Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Gene Panel Testing Should Be Done “at an Early Stage”: Chugai Official
Cancer gene panel testing kits, which received coverage under health insurance programs in Japan in June, would benefit patients in Japan as they have in the US if they could be used regardless of whether standard treatment has been completed…
To read the full story
Related Article
- Insurance Coverage of Cancer Genomic Profiling Tests in Early Stage Is Difficult: MHLW Official
October 29, 2019
- Chugai’s Comprehensive Genomic Profiling Test Approved for Companion Diagnostic for Lynparza
September 26, 2019
- Japan Still in Transition towards Comprehensive Genomic Profiling, Health Coverage Would Expand: Chugai Official
September 17, 2019
- Japan Approves Health Coverage for Cancer Gene Panel Tests
May 30, 2019
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…